TY - JOUR
T1 - Multiple cellular electrophysiological effects of a novel antiarrhythmic furoquinoline derivative HA-7 [N-benzyl-7-methoxy-2,3,4,9-tetrahydrofuro[2,3-b] quinoline-3,4-dione] in guinea pig cardiac preparations
AU - Chang, Gwo Jyh
AU - Su, Ming Jai
AU - Kuo, Sheng Chu
AU - Lin, Tsung Ping
AU - Lee, Ying Shiung
PY - 2006/1
Y1 - 2006/1
N2 - We studied the electrophysiological and antiarrhythmic actions of HA-7 [N-benzyl-7-methoxy-2,3,4,9-tetrahydrofuro[2,3-b]quinoline-3,4-dione], a furoquinoline alkaloid derivative, in guinea pig heart preparations. In the perfused whole heart model, HA-7 caused a prolongation in the basic cycle length, ventricular repolarization time, and the atrioventricular (AV) nodal Wenckebach cycle length and prolonged the refractory period of the atrium, AV node, and His-Purkinje system. The atrioventricular conduction interval was also prolonged in a frequency-dependent manner. In isolated hearts, HA-7 significantly raised the threshold for experimental atrial fibrillation and reduced the occurrence of reperfusion-induced ventricular fibrillation. Conventional microelectrode-recording study shows that HA-7, but not d-sotalol, prolonged the action potential duration (APD) and decreased the maximum rate of depolarization in isolated atrial strips. In ventricular papillary muscles, higher concentrations of HA-7 caused a prolongation of APD90 in a frequency-independent manner, whereas d-sotalol exerted a reverse frequency-dependent action on this parameter. Whole-cell patch clamp results on ventricular myocytes indicate that HA-7 decreased both the slow (IKs) (IC50 = 4.8 μM) and fast component (IKr) (IC 50 = 1.1 μM) of the delayed rectifier K+ currents. Similar results could also be observed in atrial myocytes. The inward rectifier K+ current (IK1) was also reduced somewhat by HA-7. HA-7 also suppressed the Na+ inward current (INa) (IC 50 = 2.9 μM) and inhibited the L-type Ca2+ current (ICa) (IC50 = 4.0 μM, maximal inhibition = 69%) to a lesser extent. We conclude that HA-7 blocks multiple ionic currents and that these changes affect the electrophysiological properties of the conduction system as well as the myocardial tissues and may contribute to its antiarrhythmic efficacy.
AB - We studied the electrophysiological and antiarrhythmic actions of HA-7 [N-benzyl-7-methoxy-2,3,4,9-tetrahydrofuro[2,3-b]quinoline-3,4-dione], a furoquinoline alkaloid derivative, in guinea pig heart preparations. In the perfused whole heart model, HA-7 caused a prolongation in the basic cycle length, ventricular repolarization time, and the atrioventricular (AV) nodal Wenckebach cycle length and prolonged the refractory period of the atrium, AV node, and His-Purkinje system. The atrioventricular conduction interval was also prolonged in a frequency-dependent manner. In isolated hearts, HA-7 significantly raised the threshold for experimental atrial fibrillation and reduced the occurrence of reperfusion-induced ventricular fibrillation. Conventional microelectrode-recording study shows that HA-7, but not d-sotalol, prolonged the action potential duration (APD) and decreased the maximum rate of depolarization in isolated atrial strips. In ventricular papillary muscles, higher concentrations of HA-7 caused a prolongation of APD90 in a frequency-independent manner, whereas d-sotalol exerted a reverse frequency-dependent action on this parameter. Whole-cell patch clamp results on ventricular myocytes indicate that HA-7 decreased both the slow (IKs) (IC50 = 4.8 μM) and fast component (IKr) (IC 50 = 1.1 μM) of the delayed rectifier K+ currents. Similar results could also be observed in atrial myocytes. The inward rectifier K+ current (IK1) was also reduced somewhat by HA-7. HA-7 also suppressed the Na+ inward current (INa) (IC 50 = 2.9 μM) and inhibited the L-type Ca2+ current (ICa) (IC50 = 4.0 μM, maximal inhibition = 69%) to a lesser extent. We conclude that HA-7 blocks multiple ionic currents and that these changes affect the electrophysiological properties of the conduction system as well as the myocardial tissues and may contribute to its antiarrhythmic efficacy.
UR - http://www.scopus.com/inward/record.url?scp=29244481636&partnerID=8YFLogxK
U2 - 10.1124/jpet.105.092106
DO - 10.1124/jpet.105.092106
M3 - 文章
C2 - 16174797
AN - SCOPUS:29244481636
SN - 0022-3565
VL - 316
SP - 380
EP - 391
JO - Journal of Pharmacology and Experimental Therapeutics
JF - Journal of Pharmacology and Experimental Therapeutics
IS - 1
ER -